Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

Ana Christina Garrido-Castro, MD, medical oncologist, co-director, Triple-Negative Breast Cancer Working Group, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses findings from the phase 2 SACI-IO HR+ trial (NCT04448886) evaluating sacituzumab govitecan-hziy (Trodelvy) with or without pembrolizumab (Keytruda) in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.